1. Astellas, Pfizer look to expand Xtandi’s patient base after 8 years with new prostate cancer win.FiercePharma
  2. Enzalutamide/Leuprolide prolongs MFS in nmHSPC with high-risk biochemical recurrenceTargeted oncology
  3. Pfizer, Astellas’ Xtandi meets primary endpoint in Phase 3 trial in prostate cancer subtypeSeeking Alpha
  4. Enzalutamide plus leuprolide improves MFS in nonmetastatic castration-sensitive prostate cancer.OncLive
  5. Enzalutamide plus ADT improves time to PSA progression in mHSPCTargeted oncology
  6. See full coverage on Google News

ودجت أحدث المقالات للصفحة الرئيسية تظهر على الصفحة الرئيسية فقط


Leave a Reply

Your email address will not be published. Required fields are marked *